Literature DB >> 33105485

Risk Factors for testing positive for SARS-CoV-2 in a national US healthcare system.

Vincent S Fan1, Jason A Dominitz2, McKenna C Eastment3, Emily Locke4, Pamela Green4, Kristin Berry4, Ann M O'Hare5, Javeed A Shah3, Kristina Crothers1, George N Ioannou2.   

Abstract

BACKGROUND: Identifying risk factors for SARS-CoV-2 infection could help health systems improve testing and screening strategies.
OBJECTIVES: Identify demographic factors, comorbid conditions, and symptoms independently associated with testing positive for SARS-CoV-2.
DESIGN: Observational cross-sectional study.
SETTING: Veterans Health Administration. PATIENTS: Persons tested for SARS-CoV-2 nucleic acid by polymerase chain reaction (PCR) between March 1 and May 14, 2020. MEASUREMENTS: Associations between demographic characteristics, diagnosed comorbid conditions, and documented symptoms with testing positive for SARS-CoV-2.
RESULTS: Of 88,747 persons tested, 10,131 (11.4%) were SARS-CoV-2 PCR positive. Positivity was associated with older age (≥80 vs. <50 years: aOR 2.16, 95% CI 1.97-2.37), male sex (aOR 1.45, 95% CI 1.34-1.57), regional SARS-CoV-2 burden (≥2,000 vs. <400 cases/million: aOR 5.43, 95% CI 4.97-5.93), urban residence (aOR 1.78, 95% CI 1.70-1.87), Black (aOR 2.15, 95% CI 2.05-2.26) or American Indian/Alaska Native/Pacific Islander (aOR 1.26, 95% CI 1.05-1.52) vs. White race, and Hispanic ethnicity (aOR 1.52, 95% CI 1.40-1.65). Obesity and diabetes were the only two medical conditions associated with testing positive. Documented fevers, chills, cough, and diarrhea were also associated with testing positive. The population attributable fraction of positive tests was highest for regional SARS-CoV-2 burden (35.3%), followed by demographic variables (27.2%), symptoms (12.0%), obesity (10.5%), and diabetes (0.4%). LIMITATIONS: Lack of information on SARS-CoV-2 exposures or the indications for testing which may affect the likelihood of testing positive.
CONCLUSION: The majority of positive SARS-CoV-2 tests were attributed to regional SARS-CoV-2 burden, demographic characteristics and obesity with a minor contribution of chronic comorbid conditions. Published by Oxford University Press for the Infectious Diseases Society of America 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Year:  2020        PMID: 33105485      PMCID: PMC7665412          DOI: 10.1093/cid/ciaa1624

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.

Authors:  George N Ioannou; Amy S B Bohnert; Ann M O'Hare; Edward J Boyko; Matthew L Maciejewski; Valerie A Smith; C Barrett Bowling; Elizabeth Viglianti; Theodore J Iwashyna; Denise M Hynes; Kristin Berry
Journal:  Ann Intern Med       Date:  2022-10-11       Impact factor: 51.598

2.  Application of Bayesian spatial-temporal models for estimating unrecognized COVID-19 deaths in the United States.

Authors:  Yuzi Zhang; Howard H Chang; A Danielle Iuliano; Carrie Reed
Journal:  Spat Stat       Date:  2022-01-04

3.  Factors associated with early receipt of COVID-19 vaccination and adherence to second dose in the Veterans Affairs healthcare system.

Authors:  George N Ioannou; Pamela Green; Emily R Locke; Kristin Berry
Journal:  PLoS One       Date:  2021-12-01       Impact factor: 3.240

4.  Changes in the associations of race and rurality with SARS-CoV-2 infection, mortality, and case fatality in the United States from February 2020 to March 2021: A population-based cohort study.

Authors:  George N Ioannou; Jacqueline M Ferguson; Ann M O'Hare; Amy S B Bohnert; Lisa I Backus; Edward J Boyko; Thomas F Osborne; Matthew L Maciejewski; C Barrett Bowling; Denise M Hynes; Theodore J Iwashyna; Melody Saysana; Pamela Green; Kristin Berry
Journal:  PLoS Med       Date:  2021-10-21       Impact factor: 11.613

Review 5.  Hospitalised versus outpatient COVID-19 patients' background characteristics and comorbidities: A systematic review and meta-analysis.

Authors:  Paola P Mattey-Mora; Connor A Begle; Candice K Owusu; Chen Chen; Maria A Parker
Journal:  Rev Med Virol       Date:  2021-10-21       Impact factor: 11.043

6.  Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK).

Authors:  Mohammad Talaei; Sian Faustini; Hayley Holt; David A Jolliffe; Giulia Vivaldi; Matthew Greenig; Natalia Perdek; Sheena Maltby; Carola M Bigogno; Jane Symons; Gwyneth A Davies; Ronan A Lyons; Christopher J Griffiths; Frank Kee; Aziz Sheikh; Alex G Richter; Seif O Shaheen; Adrian R Martineau
Journal:  BMC Med       Date:  2022-02-22       Impact factor: 8.775

7.  Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system.

Authors:  George N Ioannou; Emily R Locke; Pamela K Green; Kristin Berry
Journal:  EClinicalMedicine       Date:  2022-03-05

Review 8.  COVID-19 and liver disease: mechanistic and clinical perspectives.

Authors:  Thomas Marjot; Gwilym J Webb; Alfred S Barritt; Andrew M Moon; Zania Stamataki; Vincent W Wong; Eleanor Barnes
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-03-10       Impact factor: 73.082

9.  Differences in COVID-19 Risk by Race and County-Level Social Determinants of Health among Veterans.

Authors:  Hoda S Abdel Magid; Jacqueline M Ferguson; Raymond Van Cleve; Amanda L Purnell; Thomas F Osborne
Journal:  Int J Environ Res Public Health       Date:  2021-12-13       Impact factor: 3.390

10.  Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality.

Authors:  George N Ioannou; Peter S Liang; Emily Locke; Pamela Green; Kristin Berry; Ann M O'Hare; Javeed A Shah; Kristina Crothers; McKenna C Eastment; Vincent S Fan; Jason A Dominitz
Journal:  Hepatology       Date:  2021-06-02       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.